ATE202281T1 - Hormon-ersatztherapie - Google Patents

Hormon-ersatztherapie

Info

Publication number
ATE202281T1
ATE202281T1 AT94909721T AT94909721T ATE202281T1 AT E202281 T1 ATE202281 T1 AT E202281T1 AT 94909721 T AT94909721 T AT 94909721T AT 94909721 T AT94909721 T AT 94909721T AT E202281 T1 ATE202281 T1 AT E202281T1
Authority
AT
Austria
Prior art keywords
replacement therapy
hormone replacement
estrogen
antiprogestin
woman
Prior art date
Application number
AT94909721T
Other languages
English (en)
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE202281(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Application granted granted Critical
Publication of ATE202281T1 publication Critical patent/ATE202281T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
AT94909721T 1993-02-25 1994-02-18 Hormon-ersatztherapie ATE202281T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (1)

Publication Number Publication Date
ATE202281T1 true ATE202281T1 (de) 2001-07-15

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909721T ATE202281T1 (de) 1993-02-25 1994-02-18 Hormon-ersatztherapie

Country Status (25)

Country Link
US (1) US5468736A (de)
EP (1) EP0686037B1 (de)
JP (1) JP3441459B2 (de)
KR (1) KR100248857B1 (de)
AT (1) ATE202281T1 (de)
AU (1) AU680239B2 (de)
BG (1) BG62383B1 (de)
BR (1) BR9406667A (de)
CA (1) CA2157003C (de)
CZ (1) CZ290562B6 (de)
DE (1) DE69427529T2 (de)
DK (1) DK0686037T3 (de)
ES (1) ES2159552T3 (de)
FI (1) FI953926A7 (de)
GR (1) GR3036649T3 (de)
HU (1) HU221169B1 (de)
NO (1) NO309456B1 (de)
NZ (1) NZ262657A (de)
PL (1) PL176796B1 (de)
PT (1) PT686037E (de)
RO (1) RO115115B1 (de)
RU (1) RU2139056C1 (de)
SK (1) SK282921B6 (de)
UA (1) UA43842C2 (de)
WO (1) WO1994018983A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
IL148417A0 (en) * 1999-08-31 2002-09-12 Jenapharm Gmbh Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
AR035564A1 (es) * 2000-01-28 2004-06-16 Endorech Inc Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1390042B1 (de) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
WO2002094278A1 (en) * 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE347365T1 (de) * 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
DE10200405A1 (de) 2002-01-08 2002-08-01 Zimmer Ag Spinnvorrichtung und -verfahren mit Kühlbeblasung
DE10204381A1 (de) 2002-01-28 2003-08-07 Zimmer Ag Ergonomische Spinnanlage
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
DE60308679T2 (de) * 2002-06-11 2007-08-16 Pantarhei Bioscience B.V. Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
EP1511498B1 (de) * 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. Verfahren zur behandlung der menschlichen haut und hautpflegemittel zur verwendung in diesem verfahren
EP1526856B1 (de) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US8987240B2 (en) * 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ATE340580T1 (de) * 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
WO2008067086A2 (en) 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
DE602008001783D1 (de) * 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9850273B2 (en) * 2014-12-03 2017-12-26 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
LT3701944T (lt) 2015-06-18 2022-04-11 Estetra Srl Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
EP0686037A4 (de) 1997-11-26
US5468736A (en) 1995-11-21
KR100248857B1 (ko) 2000-04-01
UA43842C2 (uk) 2002-01-15
AU680239B2 (en) 1997-07-24
DK0686037T3 (da) 2001-08-27
AU6245494A (en) 1994-09-14
FI953926A0 (fi) 1995-08-22
FI953926L (fi) 1995-08-22
KR960700727A (ko) 1996-02-24
NO953243D0 (no) 1995-08-17
CZ204895A3 (en) 1996-03-13
NO953243L (no) 1995-08-17
DE69427529T2 (de) 2001-11-22
PL310660A1 (en) 1995-12-27
CA2157003C (en) 2001-04-17
ES2159552T3 (es) 2001-10-16
FI953926A7 (fi) 1995-08-22
PL176796B1 (pl) 1999-07-30
CA2157003A1 (en) 1994-09-01
CZ290562B6 (cs) 2002-08-14
JPH08510993A (ja) 1996-11-19
HU221169B1 (en) 2002-08-28
HUT72080A (en) 1996-03-28
BG62383B1 (bg) 1999-10-29
WO1994018983A1 (en) 1994-09-01
EP0686037A1 (de) 1995-12-13
BR9406667A (pt) 1996-01-23
NO309456B1 (no) 2001-02-05
HU9502306D0 (en) 1995-09-28
SK104995A3 (en) 1997-04-09
GR3036649T3 (en) 2001-12-31
RU2139056C1 (ru) 1999-10-10
NZ262657A (en) 1997-05-26
RO115115B1 (ro) 1999-11-30
JP3441459B2 (ja) 2003-09-02
EP0686037B1 (de) 2001-06-20
SK282921B6 (sk) 2003-01-09
DE69427529D1 (de) 2001-07-26
BG99880A (bg) 1996-02-28
PT686037E (pt) 2001-09-28

Similar Documents

Publication Publication Date Title
DK0686037T3 (da) Hormonsubstitutionsterapi
PT1011781E (pt) Stent com arco
NL300259I1 (nl) Huidpleisters omvattende testosteron en optioneel estrogeen.
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
DE69710896D1 (en) Progestogen-anti-progestogen therapien
AU1191383A (en) 3 keto delta4,9,19-nor steroid derivatives
ZA951880B (en) Transdermal system in the form of a patch comprising a tamoxifen derivative
MY125565A (en) Intermediates and process for preparing olanzapine
SU1090083A1 (ru) Электронно-гидромеханическая система регулирования подачей топлива
EA199700449A1 (ru) Способ предотвращения остеопороза
AU5110896A (en) Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
ES2141044A1 (es) Terapia con oxibutinina.
MX9709013A (es) Forma de dosis que comprende oxibutinina.
JO1748B1 (en) New polypeptide derivatives
SU1223536A2 (ru) Установка для электронно-лучевой сварки
MX9709426A (es) Uso de alendronato para preparar composiciones para la prevencion de la osteoporosis.
JO1813B1 (en) Slicing and forming cakes and covered with sesame
IE883607L (en) 19-nor progesterone
MX9707082A (es) Fuente luminosa de linea que incluye un colorante fluorescente.
AU122995S (en) Resuscitator case liner
AU122996S (en) Resuscitator case liner
AU122997S (en) Resuscitator case liner
JO1600B1 (en) Night feeding with different features

Legal Events

Date Code Title Description
EEFA Change of the company name